Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China flag China · Delayed Price · Currency is CNY
40.12
-1.82 (-4.34%)
Nov 17, 2026, 3:00 PM CST

SHA:688513 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
416.74855.43971.4781.23830.971,051
Trading Asset Securities
1,342758452.35741.78516.36453.84
Cash & Short-Term Investments
1,7581,6131,4241,5231,3471,505
Cash Growth
12.27%13.32%-6.52%13.04%-10.45%-7.43%
Accounts Receivable
213.49257.78288.44177.7180.92126.73
Other Receivables
0.820.310.440.661.250.17
Receivables
214.31258.09288.88178.36182.17126.9
Inventory
252.74228.71190.09160.98140.87103.68
Prepaid Expenses
-3.254.224.112.783.2
Other Current Assets
37.0428.6821.7616.4125.9740.76
Total Current Assets
2,2622,1321,9291,8831,7091,779
Property, Plant & Equipment
1,2211,2241,2491,2551,141874.59
Long-Term Investments
78.271.2180.7181.0846.66-
Goodwill
23.123.1----
Other Intangible Assets
210.81207.0135.634.4634.6133.71
Long-Term Deferred Tax Assets
16.9523.6811.58.578.7312.16
Long-Term Deferred Charges
92.1799.1777.5154.9245.3612.35
Other Long-Term Assets
33.9317.3416.7329.8932.0963.39
Total Assets
3,9393,7983,4003,3473,0182,775

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
150.64124.98144.35180.94156.86203.92
Accrued Expenses
38.41261.38266.85218.97190.72156.1
Short-Term Debt
171.2110.7174.44180.95105.2920.02
Current Portion of Long-Term Debt
4.44.43.672.93--
Current Income Taxes Payable
29.5315.14.623.341.462.71
Current Unearned Revenue
32.5623.3138.2831.9828.7110.99
Other Current Liabilities
310.7578.8264.1241.9846.3538.72
Total Current Liabilities
737.48618.7596.32661.09529.39432.46
Long-Term Debt
29.3331.5335.9339.6--
Long-Term Unearned Revenue
63.5162.4968.2541.1842.8151.03
Long-Term Deferred Tax Liabilities
43.9446.191.71.460.880.12
Total Liabilities
874.27758.9702.21743.33573.08483.6

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
176.53176.53176.53120.09120.09120.09
Additional Paid-In Capital
1,3971,4041,3881,4441,4441,444
Retained Earnings
1,5421,4191,2081,040880.3727.45
Treasury Stock
-128.78-67.67-76.22-1.59--
Comprehensive Income & Other
2.441.261.020.990.020.07
Total Common Equity
2,9892,9332,6982,6032,4442,292
Minority Interest
75.23106.14----
Shareholders' Equity
3,0653,0392,6982,6032,4442,292
Total Liabilities & Equity
3,9393,7983,4003,3473,0182,775

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
204.93146.65114.04223.48105.2920.02
Net Cash (Debt)
1,5531,4671,3101,3001,2421,485
Net Cash Growth
8.41%11.99%0.78%4.63%-16.33%-6.35%
Net Cash Per Share
9.008.427.487.347.038.43
Filing Date Shares Outstanding
173.13174.35174.08174.93176.53176.53
Total Common Shares Outstanding
173.13174.35174.08176.49176.53176.53
Working Capital
1,5251,5131,3321,2221,1801,347
Book Value Per Share
17.2716.8215.5014.7513.8512.98
Tangible Book Value
2,7562,7032,6622,5692,4102,258
Tangible Book Value Per Share
15.9215.5015.2914.5613.6512.79
Buildings
-857.74775.81724.27487.54152.45
Machinery
-789.48678.03661.8673.35279.81
Construction In Progress
-53.74189.56186.26231.12637.88